Revir Therapeutics is a biotechnology company that develops mRNA-modifying small molecules to treat Huntington's Disease and other neurogenetic disorders.

Revir Therapeutics

ReviR Therapeutics is a research and development company whose mission is to harness advanced technologies, machine learning/AI, and the inherent biology embedded within RNA to develop novel medicines to treat human disease.  Our AI-based platform allows us to expand beyond the protein-based target space to reach a large number of known disease targets previously considered “undruggable”

Strategies
* Invent and build technologies to unlock first-in-class medicines for the treatment of cancer, rare genetic disorders, and infectious diseases
* Decipher disease relevant structural and functional RNA motifs by integrating human genetic data, functional genomics, and AI 
* Integrate Machine Learning tools and advanced the mechanistic understanding of the RNA life cycle at scale in order to deliver transformative therapies for millions of patients 


Shunwei Capital

Sky9 Capital

5Y Capital

Tiantu Capital

CDH Investments

ReviR Therapeutics

We are excited to announce that CMT Research Foundation will sponsor ReviR Therapeutics to develop innovative splice-modulating therapies to treat Charcot Marie Tooth disease type 1A (CMT1A).  https://lnkd.in/gh_edswV
#CMT1A #Splicing #ReviRTherapeutics #CMTRF 
#BiotechNews #TherapeuticDevelopment

A step forward for Huntington's Disease patients today! PTC Therapeutics, Inc. announced 12 month interim data from their ongoing Phase 2 clinical trial of PTC518, a small molecule splicing modulator: evidence of being safe, tolerable, with meaningful clinical benefit: https://lnkd.in/g7NUvxkj

We are pleased to announce a significant step forward for ReviR's splicing modulators for #oncology with Asieris Pharmaceuticals! Shared passion towards cures, driven by innovation #collaboration #vision #drugdiscovery #RNA

https://lnkd.in/g6_UWbDn

We've just wrapped up an invigorating summer internship program at ReviR Therapeutics. Here's a glimpse into the experiences of our remarkable interns.

A Huge Thank You to ReviR’s Scientific Advisory Board!
We want to take a moment to express our sincere gratitude to the incredible members of ReviR’s Scientific Advisory Board.
Your collective feedback, experience, and guidance have been invaluable in shaping our direction as we continue to develop RNA modulating small molecules that are CNS penetrant and orally delivered. Your insights during our recent meeting at our South San Francisco HQ were particularly insightful and will be instrumental in helping us deliver disease modulating therapies to the patients who suffer from neurogenetic diseases, such as Huntington’s Disease. 
[SAB Members Lynne Maquat Ph.D., David Dornan Ph.D.,
Brian Safina Ph.D., Irina Antonijevic MD Ph.D., Elisabetta Morini Ph.D., Julio Medina Ph.D.].


We look forward to continuing to learn from you all and working together to achieve breakthrough therapies for patients who need them most. [ReviR members here. Not pictured Sarah Burnett, Zenia Llamas]

msh id	COM:REVIRTX
symbol	-
name	Revir Therapeutics
homepage url	https://www.revirtx.com
country	US
sector	Healthcare & Health Services
industry	Biotechnology
market	PRIVATE
employee count	24
crunchbase url	-
linkedin url	https://www.linkedin.com/company/revir-therapeutics
founders	-

market cap	-
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-
growth cost of revenue	-
growth depreciation and amortization	-
growth ebitda	-
growth ebitda ratio	-
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	-
growth gross profit ratio	-

REVI

COM:REVIRTX

Revir Therapeutics

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	-
cost of revenue	-
depreciation and amortization	-
ebitda	-
ebitda ratio	-
eps	-
eps diluted	-
operating expenses	-
operating income	-
operating income ratio	-

accounts receivables	-
capital expenditure	-
cash at beginning of period	-
cash at end of period	-
inventory	-
working capital ttm	-

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-